Market Newsdesk

LOS ANGELES, Feb. 23, 2021 (GLOBE NEWSWIRE) — BlackLine, Inc. (Nasdaq: BL) announced today that it will host a virtual Investor Day on Tuesday, March 9, 2021 beginning at 9:00 AM PT/12:00 PM ET.

Please register in advance to attend the virtual event by clicking here. The event will be live streamed and a replay will be available at https://investors.blackline.com/ for 12 months. For additional information on the event please contact BlackLine investor relations at [email protected].

About BlackLine

Companies come to BlackLine, Inc. (Nasdaq: BL) because their traditional manual accounting processes are not sustainable. BlackLine’s cloud-based solutions and market-leading customer service help companies move to modern accounting by unifying their data and processes, automating repetitive work, and driving accountability through visibility. BlackLine provides solutions to manage and automate financial close, accounts receivable and intercompany accounting processes, helping large enterprises and midsize companies across all industries do accounting work better, faster and with more control.

More than 3,400 customers trust BlackLine to help them close faster with complete and accurate results. The company is the pioneer of the financial close market and recognized as the leader by customers at leading end-user review sites including Gartner Peer Insights, G2 and TrustRadius. Based in Los Angeles, BlackLine also has regional headquarters in London, Singapore, and Sydney. For more information, please visit blackline.com

Investor Relations Contact:

Alexandra Geller
BlackLine
747.242.2863
[email protected]

ORANGE COUNTY, CA, Feb. 23, 2021 (GLOBE NEWSWIRE) — Coastline College has been awarded top ranking status for multiple degree programs by Intelligent.com, a trusted resource for online degree rankings and higher education planning.    Coastline College was listed among thousands of public institutions in the nation, and the comprehensive research guide is based on an assessment of 2,277 accredited colleges and universities. Each program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment.  

Coastline College has been a leader in online education since 1976, and offers not only AA degrees, but also a breadth of exceptional professional training and certification programs that empower students to become career-ready for jobs in today’s workforce.   Coastline also provides a wealth of transfer programs for students facilitating the opportunity to move on to a 4-year college or university.  Coastline College’s low tuition makes it one of the most affordable options in California and is one of the least-expensive schools for local students, as well as being one of the top-performing community colleges out of 115 California community colleges and ranked among the top of the 1700 nationwide community colleges.

The 2021 rankings for Intelligent.com are calculated through a unique scoring system that includes student engagement, the potential return on investment, and leading third-party evaluations. Intelligent.com analyzed thousands of schools with comparable programs on a scale of 0 to 100, with Coastline College making it to the final list for 6 Degree Programs. The methodology uses an algorithm that collects and analyzes multiple rankings into one score to easily compare each college degree program.

 

Please visit the listed sources below to access the top 3 program’s complete rankings. 

 

Associate in Psychology Degree programs | 2

https://intelligent.com//best-associate-in-psychology-degree-programs/

Accredited Certificate programs | 3

https://intelligent.com//best-accredited-certificate-programs/

 

Community Colleges | 12

https://intelligent.com//best-community-colleges/

Intelligent.com provides unbiased research to help students make informed decisions about higher education programs. The website offers curated guides which include the best degree programs as well as information about financial aid, internships and even study strategies. With comprehensive, user-friendly guides and hundreds of program rankings, Intelligent.com is a trusted source among students and prospective students.

About Coastline College:

Coastline College is accredited by the Western Association of Schools and Colleges.  For eight consecutive years, Coastline College was selected as one of the top 150 colleges by The Aspen Institute for Community College Excellence which is considered the most prestigious designation for community colleges. Coastline delivers flexible courses and services that cultivate and guide diverse student populations across the globe to complete pathways leading to the attainment of associate degrees, certificates, career readiness, and transfer to four-year colleges/universities.

Dawn Willson
Coastline College - Marketing and Communications Director
7142416186
[email protected]

SAN DIEGO, CA, Feb. 23, 2021 (GLOBE NEWSWIRE) — GreenBox POS (NASDAQ: GBOX) (the “Company”), an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions today announced its Canadian subsidiary, MoltoPay, a Money Service Business (MSB) registered and licensed with Canada’s Financial Transactions and Reports Analysis Centre (FINTRAC) has recently onboarded a new merchant client in the rapidly growing food delivery industry onto the Company’s blockchain based payment platform.

As part of the Company’s international expansion strategy, GreenBox acquired 100% of the shares of MoltoPay on August 3^rd, 2020 allowing the Company to leverage its MSB license status. Businesses choosing GreenBox as their MSB partner for Canada based business transactions benefit from not having to obtain their own license, a significant benefit in saving time and costs associated with the process. All such business transactions within the GreenBox ecosystem are therefore compliant with regulatory requirements. GreenBox’s subsidiary MSB licensing aligns perfectly with its robust blockchain based technology for processing secure payments.

“The recently onboarded merchant client is the largest of the Canada based portfolio that we have added to our platform since acquiring MoltoPay,” said Fredi Nisan, Chief Executive Officer at GreenBox POS. “The MoltoPay acquisition and MSB license provide GreenBox with a great opportunity to expand our footprint by onboarding Canadian businesses from offering secure digital payment transactions in a compliant fashion. Moving forward, we expect to see more Canada based businesses recognize the value of this offering and adopt our blockchain based payment technology.”

About GreenBox POS

GreenBox POS is an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions. The Company’s applications enable an end-to-end suite of turnkey financial products, helping to reduce fraud and improve the efficiency of handling large-scale commercial processing volumes for its merchant clients globally. For more information, please visit the Company’s website at www.greenboxpos.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission and elsewhere. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Investor Relations Contact:

Mark Schwalenberg
MZ Group – MZ North America
312-261-6430
[email protected]
www.mzgroup.us

BOCA RATON, Fla., Feb. 23, 2021 (GLOBE NEWSWIRE) — Newtek Business Services Corp., (NASDAQ: NEWT), an internally managed business development company (“BDC”), provides Newtek CEO’s, Barry Sloane, comments on the declaration of Newtek’s first quarter 2021 cash dividend of $0.50¹ per share.

Barry Sloane, President, Chairman and CEO commented, “We are pleased to report that our board has declared a first quarter 2021 dividend of $0.50 per share, payable on March 31, 2021 to our shareholders of record as of March 22, 2021. This dividend would represent a 13.6% increase over our first quarter 2020 dividend, which was impacted by the pandemic, and a 25% increase over our first quarter 2019 dividend. We believe our business model leaves us well positioned to continue to capture market opportunities, and we continue to maintain a strong outlook for 2021. We will provide company updates during our fourth quarter 2020 earnings conference call.”

Note regarding Dividend Payments: The Company’s Board of Directors expects to maintain a dividend policy with the objective of making quarterly distributions in an amount that approximates 90 – 100% of the Company’s annual taxable income. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s fiscal year based upon its taxable income for the full year and distributions paid for the full year.

¹Amount and timing of dividends, if any, remain subject to the discretion of the Company’s Board of Directors. Newtek Business Services Corp., Your Business Solutions Company^®, is an internally managed BDC, which along with its controlled portfolio companies, provides a wide range of business and financial solutions under the Newtek^® brand to the small- and medium-sized business (“SMB”) market. Since 1999, Newtek has provided state-of-the-art, cost-efficient products and services and efficient business strategies to SMB relationships across all 50 states to help them grow their sales, control their expenses and reduce their risk.

Newtek’s and its portfolio companies’ products and services include: Business Lending, SBA Lending Solutions, Electronic Payment Processing, Technology Solutions (Cloud Computing, Data Backup, Storage and Retrieval, IT Consulting), eCommerce, Accounts Receivable Financing & Inventory Financing, Insurance Solutions, Web Services, and Payroll and Benefits Solutions.

Newtek

^®
and Your Business Solutions Company^®, are registered trademarks of Newtek Business Services Corp.

Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements. Words such as “believes,” “intends,” “expects,” “projects,” “anticipates,” “forecasts,” “goal” and “future” or similar expressions are intended to identify forward-looking statements.
All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the plans, intentions and expectations reflected in or suggested by the forward-looking statements. Such risks and uncertainties include, among others, intensified competition, operating problems and their impact on revenues and profit margins, anticipated future business strategies and financial performance, anticipated future number of customers, business prospects, legislative developments and similar matters. Risk factors, cautionary statements and other conditions, which could cause Newtek’s actual results to differ from management’s current expectations, are contained in Newtek’s filings with the Securities and Exchange Commission and available through

http://www.sec.gov/

. Newtek cautions you that forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those projected or implied in these statements.

SOURCE: Newtek Business Services Corp.

Investor Relations & Public Relations


Contact: Jayne Cavuoto
Telephone: (212) 273-8179 / [email protected]

MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s fourth quarter and full year 2020 financial results will be released after market close on Monday, March 1, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2021 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 8283128. A live and archived audio webcast can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. The archived webcast will remain available on the Company’s website for fourteen (14) days following the call.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
[email protected] 

Media:
Stephanie Tomei
408.234.1279
[email protected]

Investors:
Lee Roth, Burns McClellan
212.213.0006
[email protected]

MONTRÉAL, Feb. 23, 2021 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and MD&A for its first quarter ended December 31, 2020.

Summary

• The Corporation had revenues of $13.4M for the 3 months period (297% increase from $3.4M for Q1-2020) attributable to the consolidation of the Code Bleu acquisition, and organic growth from all business units.
• The increase in the average gross margin to 28.5% (26.2% for Q1-2020) resulted from a more efficient geographical distribution of services rendered.
• The EBITDA⁽¹⁾ increased to $1.3M (512% increase from $215,545 for Q1-2020).
• Net income was $715,645 compared to $136,493 for the same period in 2020.
• The Corporation completed a $7,486,500 bought deal offering subsequently to December 31, 2020.

“The first quarter of 2021 has set the pace for the reminder of FY2021.” Said Martin Legault, CEO of Premier Health. “Premier Health’s results for this quarter are above our budget and we are continuing on our growth path.”

First Quarter 2021 Results Highlights

	December 31, 2020 (3 months)			December 31, 2019 (3 months)
Revenues	$ 13,360,309			$ 3,364,158
From last period		+297	%
Gross margin	$ 3,803,468			$ 884,605
From last period		+330	%
EBITDA (1)	$ 1,318,718			$ 215,545
From last period		+512	%
Net Income	$ 715,645			$ 136,493
From last period		+424	%

⁽¹⁾ Adjusted EBITDA before non-recurring items

Business Highlights

• The integration of the Code Bleu acquisition is proceeding as planned.
• The Corporation provided over 200,000 hours of services during the quarter.
• The Nordik business unit represented 24% of Premier Health’s revenues and had an increasingly positive impact on the Corporation’s average gross margin.
• Work protocols are adapting to COVID-19 and management at healthcare networks are gradually realizing that a better integration of public infrastructure and private solutions enables a better continuity of service to the population.

Financing Highlights

• The Corporation issued an aggregate of 7,130,000 common shares at a price of $1.05 per share for aggregate gross proceeds of $7,486,500 on a bought deal basis on February 22, 2021.

Completion of Code Bleu Acquisition

Premier Health completed the previously announced Code Bleu acquisition on November 6 for a total consideration of C$17 million. The acquisition was financed by a $10M term loan, the issuance of 6,521,740 common shares of the Corporation at $0.69 per share and a $2.5M balance of sale subject to performance objectives. Code Bleu’s Q1-2021 partial consolidation (55 days over a 92 day quarter) added over 87,000 billed hours and revenues of $5.3M to Premier Health’s results.

About Premier Health

Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of staffing and outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary PSweb platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper and more accessible care services.

Non-GAAP Measures

Earnings before interest, taxes, depreciation and amortization (“EBITDA”), is calculated as the net profit (loss), before non-recurring items such as acquisition and transaction costs, non-cash expenses (including loss from disposal of assets, impairments, amortization and depreciation), interest expense, net of interest income and income tax expense.

For Further Information Please Contact:

Mr. Jean-Robert Pronovost
Vice-President, Corporate Development
Premier Health of America Inc.
[email protected] / 1 800 231 9916

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Corporation’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedar.com.

PLEASANTON, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) — Workday, Inc. (NASDAQ: WDAY), a leader in enterprise cloud applications for finance and human resources, today announced that Aneel Bhusri, co-founder and co-CEO of Workday, will present at the Morgan Stanley Technology, Media and Telecom Conference on Monday, March 1, at 12:30 p.m. Pacific Time / 3:30 p.m. Eastern Time. Individuals may access the live webcast of the presentation here.

A replay of the presentation will be available on the Workday Investor Relations site for a minimum of 30 days after the conference takes place.

About Workday

Workday is a leading provider of enterprise cloud applications for finance and human resources, helping customers adapt and thrive in a changing world. Workday applications for financial management, human resources, planning, spend management, and analytics have been adopted by thousands of organizations around the world and across industries – from medium-sized businesses to more than 45 percent of the Fortune 500. For more information about Workday, visit workday.com.

© 2021 Workday, Inc. All rights reserved. Workday and the Workday logo are registered trademarks of Workday, Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.

Investor Relations Contact:

Justin Furby
[email protected]

Media Contact: 
Nina Oestlien
[email protected]

CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced it has priced an underwritten public offering of 4,622,000 American Depositary Shares, each representing two ordinary shares, at an offering price of $8.50 per American Depositary Share. The gross proceeds from the offering will be approximately $39,287,000, before deducting underwriting discounts and commissions and estimated offering expenses. BrainsWay has also granted the underwriters a 30-day option to purchase up to an additional 693,300 American Depositary Shares on the same terms and conditions. The closing of the offering is expected to take place on February 25, 2021, subject to the satisfaction of customary closing conditions.

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. Ladenburg Thalmann & Co. Inc. and Northland Capital Markets are acting as co-managers for the offering.

BrainsWay intends to use the net proceeds of the offering, together with its existing cash and cash equivalents, for commercial expansion and general corporate purposes, which may include working capital, research and development activities, commercialization and marketing activities, regulatory matters, capital investment and/or other related purposes.

The securities described above are being offered by BrainsWay pursuant to a shelf registration statement (File No. 333-248601) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on October 16, 2020, and the accompanying prospectus contained therein. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC, and are available on the SEC’s website at http://www.sec.gov. When available, copies of the final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be available on the website of the SEC and may also be obtained from: Oppenheimer & Co. Inc. at 85 Broad Street, 26th Floor, New York, NY 10004, Attention: Equity Syndicate Prospectus Department, by e-mail at [email protected] or by calling (212) 667-8055.

Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that BrainsWay has filed with the SEC that are incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which provide more information about BrainsWay and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BrainsWay

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, but are not limited to, statements about the expected proceeds, use of proceeds and closing of the underwritten offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 23, 2020. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.

Contact:

BrainsWay:
Hadar Levy
SVP and General Manager
[email protected]

Appointments Expected to Strengthen Sales Organization and Drive growth

FREDERICK, Md., Feb. 23, 2021 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.^® (“TOMI”, “the Company”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology Platform through its SteraMist products – a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP™), has announced the appointment of the new sales vice presidents: Gary Zamieroski as Vice President, Sales for the Commercial division, Patrick Griffin as Vice President, Sales for the Hospital-HealthCare division and Kim Larkin as Vice President, Sales of the Food Safety division.

Gary Zamieroski, Vice President Sales for the Commercial division, brings 35 years’ global executive leadership experience in sales, marketing, strategy, business development, government affairs and technology development in the aerospace, defense, energy, and high-tech industries with companies such as GE, Honeywell, Textron, and Airbus.

“I see clear growth potential for boosting TOMI’s sales in its commercial division https://tomimist.com/industries-divisions/commercial/ globally through coordinated sales and marketing and account-based marketing activities,” commented Mr. Zamieroski.

 Patrick Griffin joins TOMI as Vice President, Sales for Hospital-HealthCare; https://tomimist.com/industries-divisions/hospital-healthcare/, bringing over 25 years of experience in the Healthcare space including working for Quest Diagnostics, Abbott, Siemens Bayer and ThermoFisher Scientific. Some of the characteristics that have led to his success are his effective strategic vision, financial management and budgeting acumen, contract execution and team building capabilities. Throughout his career he has held positions of increasing responsibility and has built and led teams in sales, marketing, operations and training.
“This is an exciting time to join TOMI and I look forward to being part of an organization that provides cutting edge technology to help our customers in the healthcare industry keep patients and first-responders safe,” stated Mr. Griffin.

Kim Larkin , Vice President, Sales for the Food Safety division; https://tomimist.com/industries-divisions/food-safety/ joins TOMI, having spent the past few years with leading TIC (Testing, Inspection & Certification) companies. She also brings experience from her work with food safety diagnostic companies including 3M, NSF International and Intertek.  Her focus on food safety started over 20 years ago as a student at Colorado State University working in the Meat Science Microbiology lab, where she learned it takes an entire community working together globally to create a better and safer food supply.

Ms. Larkin stated, “I am excited to join TOMI with its game-changing SteraMist technology, that is nothing like the food industry has ever seen. The non-corrosive and easy to use organic registration opens the door for so many to improve speed of disinfection and achieve a better pathogen reduction. 

Halden Shane, CEO of TOMI, stated, “TOMI is focused on growing out market share and revenue from the global disinfectant and decontamination market, which is valued at nearly $19 billion with a growing CAGR of 6.7%. In light of the recent completion of R&D and anticipated launch of our new product line in approximately six weeks, this is the ideal time for us to onboard senior divisional sales professionals to take the lead closing on business from our growing sales pipeline. It is important to introduce SteraMist to all sectors of all industries. TOMI’s is currently a leader in disinfection and decontamination globally, and our goal is to establish our Company as the worldwide standard in our industry. We believe these three new hires should be a giant step in furthering TOMI’s worldwide market recognition, driving our growth and accelerating our progress toward becoming that standard.”

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world

^®
 

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology^® (BIT^™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT^™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP^™). Represented by the SteraMist^® brand of products, iHP^™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit http://www.tomimist.com/ or contact us at [email protected].

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

INVESTOR RELATIONS CONTACT

John Nesbett/Jennifer Belodeau
IMS Investor Relations
[email protected]